Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

ATI Inc. manufactures and sells specialty materials and components worldwide. The company operates in two segments: High Performance Materials & Components (HPMC) and Advanced Alloys & Solutions (AA&S). The HPMC segment produces various materials, including titanium and titanium-based alloys, nickel- and cobalt-based alloys and superalloys, advanced powder alloys and other specialty materials, in long product forms, such as ingot, billet, bar, rod, wire, shapes and rectangles, and seamless tubes, as well as precision forgings, components, and machined parts. The segment serves aerospace and defense, medical, and energy markets. The AA&S segment produces zirconium and related alloys, including hafnium and niobium, nickel-based alloys, titanium and titanium-based alloys, and specialty alloys in a variety of forms, such as plate, sheet, and precision rolled strip products. It also provides hot-rolling conversion services, including carbon steel products, and titanium products. This segment offers its solutions to the energy, aerospace and defense, automotive, and electronics markets. The company was formerly known as Allegheny Technologies Incorporated. ATI Inc. was founded in 1960 and is headquartered in Dallas, Texas.

ATI Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

- POSITIVE RESULTS FROM PHASE 2A TRIAL OF ITK/JAK3 INHIBITOR ATI-2138 PRESENTED AT THE 2025 EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (EADV) CONGRESS, FURTHER VALIDATING ITK AS THERAPEUTIC TARGET; INITIATION OF PHASE 2 TRIAL IN AN ADDITIONAL INDICATION EXPECTED IN THE FIRST HALF OF 2026 - - TIMELINES REITERATED FOR TOP LINE CLINICAL RESULTS FROM ONGOING TRIALS OF INVESTIGATIONAL ANTI-TSLP MONOCLONAL ANTIBODY BOSAKITUG (ATI-045) AND ANTI-TSLP/IL-4R BISPECIFIC ANTIBODY ATI-052 - - INITIATION OF PHASE 1B PROOF-OF-CONCEPT TRIALS OF ATI-052 IN ASTHMA AND ATOPIC DERMATITIS (AD) EXPECTED IN THE FIRST HALF OF 2026 - - STRONG CASH RUNWAY EXPECTED TO FUND OPERATIONS INTO THE SECOND HALF OF 2028 - WAYNE, PA., NOV. 06, 2025 (GLOBE NEWSWIRE) -- ACLARIS THERAPEUTICS, INC. (NASDAQ: ACRS), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING NOVEL PRODUCT CANDIDATES FOR IMMUNO-INFLAMMATORY DISEASES, TODAY ANNOUNCED ITS FINANCIAL RESULTS FOR THE THIRD QUARTER OF 2025 AND PROVIDED A CORPORATE UPDATE.

ACLARIS THERAPEUTICS REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

CONTINUED YEAR-OVER-YEAR SALES GROWTH DRIVEN BY AEROSPACE & DEFENSE RECORD AEROSPACE & DEFENSE SALES OF $793 MILLION, REPRESENTING 70% OF Q 3 2025 SALES STRONG MARGIN PERFORMANCE IN HPMC AND AA&S SEGMENTS RAISING FULL YEAR RANGES FOR ADJUSTED EARNINGS AND CASH FLOW GUIDANCE THIRD QUARTER 2025 GAAP FINANCIAL RESULTS SALES OF $1.13 BILLION, UP 7% YEAR-OVER-YEAR, DRIVEN BY A 21% AEROSPACE & DEFENSE INCREASE NET INCOME ATTRIBUTABLE TO ATI OF $110 MILLION, UP 33% YEAR-OVER-YEAR EARNINGS PER SHARE OF $0.78 COMPARED TO $0.57 PER SHARE IN THE THIRD QUARTER 2024 THIRD QUARTER 2025 NON-GAAP FINANCIAL INFORMATION* ADJUSTED NET INCOME ATTRIBUTABLE TO ATI* OF $119 MILLION, UP 39% YEAR-OVER-YEAR ADJUSTED EARNINGS PER SHARE* OF $0.85, COMPARED TO $0.60 PER SHARE IN THE THIRD QUARTER 2024 ADJUSTED EBITDA* OF $225 MILLION, AN INCREASE OF 21% YEAR-OVER-YEAR ADJUSTED EBITDA* AS A PERCENTAGE OF SALES OF 20.0%, COMPARED TO 17.7% IN THE THIRD QUARTER 2024 GUIDANCE THE COMPANY IS PROVIDING FOURTH QUARTER AND UPDATED FULL YEAR 2025 GUIDANCE IN THE TABLE BELOW. CURRENT GUIDANCE PRIOR GUIDANCE Q4 2025 FULL YEAR 2025 FULL YEAR 2025 ADJUSTED EBITDA** $221M - $231M $848M - $858M $810M - $840M ADJUSTED EARNINGS PER SHARE** $0.84 - $0.90 $3.15 - $3.21 $2.90 - $3.07 ADJUSTED FREE CASH FLOW** $330M - $370M $270M - $350M CAPITAL EXPENDITURES $260M - $280M $260M - $280M *RECONCILIATIONS OF THE REPORTED INFORMATION UNDER ACCOUNTING PRINCIPLES GENERALLY ACCEPTED IN THE UNITED STATES (GAAP) TO NON-GAAP FINANCIAL MEASURES ARE INCLUDED IN ACCOMPANYING FINANCIAL TABLES.

ATI ANNOUNCES THIRD QUARTER 2025 RESULTS

TORONTO, OCT. 16, 2025 (GLOBE NEWSWIRE) -- ALTAI RESOURCES INC. (TSXV: ATI) (ALTAI OR THE COMPANY) ANNOUNCED TODAY THAT FURTHER TO THE COMPANY'S NEWS RELEASE DATED SEPTEMBER 4, 2025 REGARDING THE DECLARATION BY THE BOARD OF DIRECTORS OF THE COMPANY OF A SPECIAL CASH DISTRIBUTION OF $0.06 PER COMMON SHARE (THE SPECIAL CASH DISTRIBUTION), THE COMPANY HAS COMPLETED THE PAYMENT OF THE SPECIAL CASH DISTRIBUTION BY WAY OF A RETURN OF CAPITAL. THE TOTAL AMOUNT PAID BY THE COMPANY FOR THE SPECIAL CASH DISTRIBUTION WAS APPROXIMATELY $3.4 MILLION, WHICH WAS FUNDED FROM THE COMPANY'S CASH AND CASH EQUIVALENTS.AS OF TODAY'S DATE, THE COMPANY HAS APPROXIMATELY $0.7 MILLION OF CASH AND CASH EQUIVALENTS REMAINING, OR APPROXIMATELY $0.013 PER COMMON SHARE BASED ON THE TOTAL ISSUED AND OUTSTANDING COMMON SHARES OF 56,033,552. AS OF TODAY'S DATE, THE COMPANY IS DEBT-FREE.

ALTAI ANNOUNCES COMPLETION OF SPECIAL CASH DISTRIBUTION TO SHAREHOLDERS

DALLAS , SEPT. 30, 2025 /PRNEWSWIRE/ -- ATI (NYSE: ATI) HAS SCHEDULED THE LIVE WEBCAST FOR ITS THIRD QUARTER 2025 EARNINGS CONFERENCE CALL ON TUESDAY, OCTOBER 28, 2025, AT 7:30 A.M.

ATI ANNOUNCES WEBCAST FOR THIRD QUARTER 2025 RESULTS

TORONTO, SEPT. 29, 2025 (GLOBE NEWSWIRE) -- ALTAI RESOURCES INC. (TSXV: ATI) (ALTAI OR THE COMPANY) ANNOUNCED TODAY THAT IT HAS SOLD ITS OWNERSHIP OF A 50% WORKING INTEREST IN THE OIL WELLS PROPERTY LOCATED IN CESSFORD, ALBERTA, COMPRISED OF 4 OIL WELLS (THE CESSFORD OIL WELLS PROPERTY), TO THE OWNER OF THE OTHER 50% WORKING INTEREST, AND THE PROPERTY'S OPERATOR, CANADIAN NATURAL RESOURCES LIMITED (CNRL), FOR A NET LIABILITY SETTLEMENT OF $50,674 (THE NET LIABILITY SETTLEMENT), WHICH IS COMPRISED OF THE SALE OF THE ASSET PORTION AND THE SETTLEMENT OF THE LIABILITY PORTION. THE NET LIABILITY SETTLEMENT HAS BEEN PAID FOR BY AN INTER-BANK CASH TRANSFER FROM THE COMPANY TO CNRL. THE NET LIABILITY SETTLEMENT REPRESENTS A GAIN OF $111,728 (OR APPROXIMATELY 69%) OVER THE COMPANY'S DECOMMISSIONING LIABILITY, NET OF THE CARRYING VALUE OF THE ASSET, FOR THE CESSFORD OIL WELLS PROPERTY AS REPORTED IN THE COMPANY'S MOST RECENT INTERIM CONSOLIDATED FINANCIAL STATEMENTS FOR THE PERIOD ENDED JUNE 30, 2025.

ALTAI ANNOUNCES SALE OF CESSFORD OIL WELLS PROPERTY

'NEEDLECERT PRIVILEGEPATH' DRIVES EXCEPTIONAL LEARNER ADOPTION AND CLINICAL CONSISTENCY DOWNERS GROVE, ILL. , SEPT. 25, 2025 /PRNEWSWIRE/ -- ATI PHYSICAL THERAPY, A NATIONALLY RECOGNIZED PROVIDER OF OUTPATIENT PHYSICAL THERAPY AND REHABILITATION SERVICES, HAS BEEN NAMED THE WINNER OF THE BEST TRAINING ADOPTION AWARD IN ABSORB SOFTWARE'S 2025 ABSORBIES AWARDS, WHICH RECOGNIZES VISIONARY INDIVIDUALS AND ORGANIZATIONS THAT ARE RESHAPING LEARNING AND DEVELOPMENT (L&D) THROUGH CREATIVITY, MEASURABLE IMPACT, AND INCLUSIVE EXCELLENCE.

ATI PHYSICAL THERAPY RECOGNIZED FOR COMMITMENT TO SAFETY IN USE OF DRY NEEDLING

APPOINTMENTS OF EXPERIENCED LEADERS STRENGTHEN ATI'S POSITION AS AEROSPACE AND DEFENSE LEADER DALLAS , SEPT. 10, 2025 /PRNEWSWIRE/ -- ATI INC. (NYSE: ATI) TODAY ANNOUNCED THE APPOINTMENT OF TWO PROVEN AEROSPACE EXECUTIVES, ELIZABETH LUND AND JEAN LYDON-RODGERS, TO ITS BOARD OF DIRECTORS EFFECTIVE NOVEMBER 1, 2025.

ATI NAMES AEROSPACE LEADERS TO BOARD TO DRIVE GROWTH

SEARCH FOR SUCCESSOR UNDERWAY DALLAS , SEPT. 10, 2025 /PRNEWSWIRE/ -- ATI INC. (NYSE: ATI) TODAY ANNOUNCED THAT EXECUTIVE VICE PRESIDENT - FINANCE AND CHIEF FINANCIAL OFFICER DON NEWMAN HAS INFORMED THE COMPANY HE WILL RETIRE MARCH 1, 2026.

ATI CHIEF FINANCIAL OFFICER DON NEWMAN ANNOUNCES RETIREMENT

- LATE BREAKING ABSTRACT TO PRESENT ADDITIONAL DATA FROM ACLARIS' PHASE 2A TRIAL OF ATI-2138 IN ATOPIC DERMATITIS- WAYNE, PA., SEPT. 09, 2025 (GLOBE NEWSWIRE) -- ACLARIS THERAPEUTICS, INC. (NASDAQ: ACRS), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING NOVEL PRODUCT CANDIDATES FOR IMMUNO-INFLAMMATORY DISEASES, TODAY ANNOUNCED THAT A LATE-BREAKING ABSTRACT ON ITS OPEN-LABEL PHASE 2A TRIAL OF ATI-2138, A POTENT AND SELECTIVE INVESTIGATIONAL ORAL COVALENT INHIBITOR OF INTERLEUKIN-2-INDUCIBLE T CELL KINASE (ITK) AND JANUS KINASE 3 (JAK3), WAS SELECTED FOR ORAL PRESENTATION AT THE 2025 EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (EADV) CONGRESS, BEING HELD SEPTEMBER 17-20, 2025, IN PARIS, FRANCE.

ACLARIS THERAPEUTICS ANNOUNCES LATE-BREAKING ABSTRACT AND ORAL PRESENTATION ON ATI-2138 PHASE 2A RESULTS AT THE 2025 EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (EADV) CONGRESS

EAST HARTFORD OPERATIONS IS A LEADING SUPPLIER OF FLIGHT-SAFETY CRITICAL COMPONENTS AND ASSEMBLIES FOR THE COMMERCIAL AND DEFENSE AEROSPACE SECTORS. MESIROW ACTED AS THE EXCLUSIVE FINANCIAL ADVISOR ON THIS CORPORATE DIVESTITURE TRANSACTION, HIGHLIGHTING THE FIRM'S CONTINUED SUCCESS IN THE AEROSPACE & DEFENSE SECTOR.

MESIROW ADVISES ATI ON THE SALE OF ATI'S EAST HARTFORD OPERATIONS TO BARNES AEROSPACE

PEER-REVIEWED PUBLICATION HIGHLIGHTS ATI-1701'S ROBUST PROTECTION AGAINST AEROSOLIZED FRANCISELLA TULARENSIS EXPOSURE IN MULTIPLE ANIMAL MODELS

APPILI THERAPEUTICS AND COLLEAGUES PUBLISH MANUSCRIPT DEMONSTRATING EFFICACY OF ATI-1701 TULAREMIA VACCINE

ATI PHYSICAL THERAPY TRANSITIONS FROM PUBLIC TO PRIVATE OWNERSHIP MOVE TO PRIVATE OWNERSHIP SUPPORTS LONG-TERM GROWTH, OPERATIONAL FLEXIBILITY, AND CONTINUED FOCUS ON PATIENT CARE DOWNERS GROVE, ILL. , AUG. 1, 2025 /PRNEWSWIRE/ -- ATI PHYSICAL THERAPY, INC. ("ATI") (OTCMKTS: ATIP), A NATIONALLY RECOGNIZED PROVIDER OF OUTPATIENT PHYSICAL THERAPY AND REHABILITATION SERVICES, TODAY ANNOUNCED THAT A CONSORTIUM OF EXISTING STOCKHOLDERS, HOLDING OVER 90% OF THE VOTING SHARES AND LED BY PRIVATE INVESTMENT FIRMS, KNIGHTHEAD CAPITAL MANAGEMENT AND MARATHON ASSET MANAGEMENT, COMPLETED A MERGER TO TAKE THE COMPANY PRIVATE.

ATI Inc.

ATI

Price

Financials Overview

Financial Reports

No items found.

Press Releases

ATI Inc.

ATI.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

ATI